(1-hydroxy-1-phosphonoethyl)phosphonic acid

• ChemBase ID: 948
• Molecular Formular: C2H8O7P2
• Molecular Mass: 206.028242
• Monoisotopic Mass: 205.97452586
• SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)C
• Canonical SMILES: CC(P(=O)(O)O)(P(=O)(O)O)O
• InChI: InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
• InChIKey: DBVJJBKOTRCVKF-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (1-hydroxy-1-phosphonoethyl)phosphonic acid
• IUPAC Traditional name: etidronic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid
• Brand Name: Cintichem Technetium 99m Hedspa; Dequest 2010; Dequest 2015; Dequest Z 010; Didronel; Didronel IV; Ferrofos 510; MPI Stannous Diphosphonate; Osteoscan; Turpinal SL
• Synonyms: Didronel; Etidronate; Acetodiphosphonic acid; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; EHDP; Etidronate Disodium; Etidronsaeure; HEDP; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Etidronate; Etidronic acid; HDEPA; OEDFK; Etidronic acid; Etidronic acid; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethylidenebis(phosphonic acid); Ksidifon; Xidiphone; Etidronate; (1-hydroxyethane-1,1-diyl)diphosphonic acid; 羟基乙叉二膦酸; 羟基亚乙基二膦酸; 依替膦酸; 乙烷-1-羟基-1,1-二磷酸

Database IDs

• CAS Number: 2809-21-4; 7414-83-7
• EC Number: 220-552-8
• MDL Number: MFCD00070585
• Beilstein Number: 1789291
• Merck Index: 143863
• PubChem SID: 160964411; 46507694; 24895766
• PubChem CID: 3305

CALCULATED PROPERTIES

JChem

• Acid pKa: 0.6962425
• H Acceptors: 7
• H Donor: 5
• LogD (pH = 5.5): -6.886243
• LogD (pH = 7.4): -7.207523
• Log P: -2.2774973
• Molar Refractivity: 34.511 cm^3
• Polarizability: 14.175921 Å^3
• Polar Surface Area: 135.29 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: -0.77
• LOG S: -1.25
• Solubility (Water): 1.15e+01 g/l

PROPERTIES

Physical Property

• Apperance: Powder
• Hydrophobicity(logP): -3.8

Safety Information

• Storage Condition: -20°C
• RTECS: SZ8562100
• European Hazard Symbols: Corrosive (C); Irritant (Xi)
• UN Number: UN3261
• German water hazard class: 2
• Hazard Class: 8
• Packing Group: III
• Risk Statements: 34; 41
• Safety Statements: 26-36/37/39-45; 26-39
• TSCA Listed: 是
• GHS Pictograms: GHS05; GHS07; GHS09
• GHS Signal Word: Danger
• GHS Hazard statements: H314-H318-H302; H318-H410
• GHS Precautionary statements: P260-P303+P361+P353-P305+P351+P338-P301+P330+P331-P405-P501A; P273-P280-P305 + P351 + P338-P501
• Personal Protective Equipment: Eyeshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter

Pharmacology Properties

• Mechanism of Action: Bone resorption inhibitor; Chelator; Reduces the number of osteoclasts in active bone turnover-sites

Product Information

• Purity: 96%
• Salt Data: Free Base
• Suitability: suitable for photographic applications
• Application(s): This medicine is used to treat Paget's Disease, and to treat conditions of irregular bone growth due to hip fracture or spinal cord injury

DETAILS

DrugBank - DB01077

• Drug Groups: approved
• Description: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]
• Indication: For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
• Pharmacology: Etidronic acid is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronic acid affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronic acid that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronic acid has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.
• Toxicity: Clinical experience with acute etidronic acid overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.
• Affected Organisms: Humans and other mammals
• Biotransformation: Not metabolized.
• Absorption: The amount of drug absorbed after an oral dose is approximately 3%.
• Half Life: In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.
• Elimination: Etidronate disodium is not metabolized. Within 24 hours, approximately half the absorbed dose is excreted in urine; the remainder is distributed to bone compartments from which it is slowly eliminated. Unabsorbed drug is excreted intact in the feces.
• External Links: Wikipedia; RxList

Selleck Chemicals - S1857

Research Area: Cancer
Biological Activity:

Sigma Aldrich - H6773

包装
100, 500 g in poly bottle
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. H6773.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

REFERENCES

• Pribil, R. et al., Talanta, 1967, 14, 591, (use)
• Kasparek, F., Monatsh. Chem., 1968, 99, 2016, (synth)
• Strates, B.S. et al., Biochim. Biophys. Acta, 1971, 244, 121, (pharmacol)
• Wiers, B.H., Inorg. Chem., 1971, 10, 2581, (salts)
• Michael, W.R. et al., Toxicol. Appl. Pharmacol., 1972, 21, 503, (metab)
• Bikhman, B.I. et al., Zh. Neorg. Khim., 1973, 18, 2406; Russ. J. Inorg. Chem. (Engl. Transl.), 1973, 18, 1273, (ir, salts)
• Collins, A.J. et al., J. Appl. Chem. Biotechnol., 1977, 27, 651, (props, salts)
• De Angelis, L., Drugs of Today (Barcelona), 1978, 14, 101, (rev, pharmacol)
• Barnett, B.L. et al., Acta Cryst. B, 1979, 35, 1212, (cryst struct)
• Worms, K.H. et al., Z. Anorg. Allg. Chem., 1979, 457, 209, (synth)
• Motekaitis, R.J. et al., Inorg. Chem., 1980, 19, 1646, (props, complexes)
• Rizhalla, E.N. et al., Talanta, 1980, 27, 715, (complexes)
• Goeva, L.V., Radiokhimiya, 1982, 22, 591; Sov. Radiochem. (Engl. Transl.), 1982, 22, 489, (props)
• Fonong, T. et al., Anal. Chem., 1983, 55, 1089, (props)
• Van der Pol, H.J., Pharm. Weekbl., 1983, 118, 330, (anal, props)
• Perfil'ev, V.A. et al., Zh. Anal. Khim., 1984, 39, 2133, (detn, V)
• Afonin, E.G. et al., Zh. Obshch. Khim., 1987, 57, 538; 1989, 59, 317; J. Gen. Chem. USSR (Engl. Transl.), 1987, 57, 469; 1989, 59, 273, (acid, salts, ir)
• Fleisch, H., Bisphosphonates and Tumor Osteolysis, (Brunner, K.W. et al, ed.), Springer-Verlag, Berlin, 1989, 1, (rev)
• Shkol'nikova, L.M. et al., Kristallografiya, 1991, 36, 77; Sov. Phys. Crystallogr. (Engl. Transl.), 1991, 36, 40, (cryst structs)
• Kashina, N.A. et al., Zh. Obshch. Khim., 1992, 62, 1567; J. Gen. Chem. USSR (Engl. Transl.), 1992, 62, 1284, (props)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 658
• Encyclopedia of Food and Color Additives, (ed. Burdock, G.A.), CRC Press, 1997, 1371-1372
• Osvath, R., Food Chem. News, 2001, 43(32), 11, (use)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, DXD400; TEE250; TNL750; HKS780